About TSSNF
Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. It operates through the following segments: dCELL, BioRinse, GBM-V, and Central. The dCELL segment technology platform removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold. The BioRinse segment offers sterile tissue prepared in a manner to minimise the negative effects of processing. The GBM-V segment is a regional tissue bank based in Rostock, Germany, which currently produces tissue preparations for ophthalmology. The company was founded by Eileen Ingham and John Fisher in May 2006 and is headquartered in Leeds, the United Kingdom.